# Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

> **NCT02600169** · — · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 150 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pemprolizumab

## Key facts

- **NCT ID:** NCT02600169
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2019-04
- **Final completion:** 2019-04
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2024-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02600169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02600169, "Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02600169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*